Categories: News

Bioventus to Report Second Quarter of Fiscal Year 2022 Financial Results on August 11, 2022

DURHAM, N.C., July 26, 2022 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the second quarter of fiscal year 2022 before the market opens on Thursday, August 11, 2022. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update.

To participate in the conference call, dial 1-833-636-0497 (domestic) or +1-412-902-4241 (international) and refer to the Bioventus, Inc. Conference Call.

A live webcast of the call and accompanying materials will also be provided on the “Investor Relations” section of the Company’s website at https://ir.bioventus.com/. The webcast will be archived at the same site and available for replay until August 10, 2023.

About Bioventus
Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for Pain Treatments, Restorative Therapies and Surgical Solutions. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com and follow the Company on LinkedIn and Twitter. Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.

Investor and Media Inquiries:
Dave Crawford
919-474-6787
Dave.Crawford@bioventus.com

Staff

Recent Posts

KORU Medical Systems Receives FDA 510(k) Clearance for Delivery of RYSTIGGO® (rozanolixizumab-noli), Expanding Label for FreedomEDGE® Infusion System

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading…

52 minutes ago

Hologic Announces Financial Results for First Quarter of Fiscal 2026

– Revenue of $1,047.8 Million Grows 2.5% – – GAAP Diluted EPS of $0.79 Decreases…

56 minutes ago

Illumina completes acquisition of SomaLogic

Deeply expands leadership in proteomics and multiomicsCombined capabilities bring high scalability, flexibility, and affordability into protein…

1 hour ago

RazorMetrics Drives More Than $11 Million in Prescription Drug Savings for Ohio Plans and Residents

AUSTIN, Texas, Jan. 30, 2026 /PRNewswire/ -- RazorMetrics, a leading innovator in pharmacy cost containment…

1 hour ago

NYSE Content Advisory: Pre-Market Update + Cast of HBO’s ‘Industry’ Rang Thursday’s Closing Bell

NEW YORK, Jan. 30, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a…

1 hour ago

VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays

HENDERSON, Nev., Jan. 30, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national…

1 hour ago